{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:41:05Z","timestamp":1788579665038,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T00:00:00Z","timestamp":1731801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CIVICs, 75N93019C00051"],"award-info":[{"award-number":["CIVICs, 75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CEIRR,75N93021C00014"],"award-info":[{"award-number":["CEIRR,75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["P01 AI097092-07"],"award-info":[{"award-number":["P01 AI097092-07"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01 AI145870-03"],"award-info":[{"award-number":["R01 AI145870-03"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CIVICs, 75N93019C00051"],"award-info":[{"award-number":["CIVICs, 75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CEIRR,75N93021C00014"],"award-info":[{"award-number":["CEIRR,75N93021C00014"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["CIVICs, 75N93019C00051"],"award-info":[{"award-number":["CIVICs, 75N93019C00051"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"DOI":"10.1038\/s41541-024-01014-8","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T05:36:50Z","timestamp":1731821810000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7920-5505","authenticated-orcid":false,"given":"Irene","family":"Gonz\u00e1lez-Dom\u00ednguez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2816-7051","authenticated-orcid":false,"given":"Eduard","family":"Puente-Massaguer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2024-109X","authenticated-orcid":false,"given":"Adam","family":"Abdeljawad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsoi Ying","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3751-8036","authenticated-orcid":false,"given":"Madhumathi","family":"Loganathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Lemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Dolange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3694-6597","authenticated-orcid":false,"given":"Stefan","family":"Slamanig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Mart\u00ednez-Guevara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4121-776X","authenticated-orcid":false,"given":"Florian","family":"Krammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0337-5823","authenticated-orcid":false,"given":"Peter","family":"Palese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-5047","authenticated-orcid":false,"given":"Weina","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"key":"1014_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","volume":"4","author":"F Krammer","year":"2018","unstructured":"Krammer, F. et al. Influenza. Nat. Rev. Dis. Prim. 4, 3 (2018).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"1014_CR2","unstructured":"CDC. https:\/\/www.cdc.gov\/flu\/index.htm (2023)."},{"key":"1014_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1128\/mr.56.1.152-179.1992","volume":"56","author":"RG Webster","year":"1992","unstructured":"Webster, R. G., Bean, W. J., Gorman, O. T., Chambers, T. M. & Kawaoka, Y. Evolution and ecology of influenza A viruses. Microbiol Rev. 56, 152\u2013179 (1992).","journal-title":"Microbiol Rev."},{"key":"1014_CR4","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1586\/14760584.2013.824709","volume":"12","author":"C Hannoun","year":"2013","unstructured":"Hannoun, C. The evolving history of influenza viruses and influenza vaccines. Expert Rev. Vaccines 12, 1085\u20131094 (2013).","journal-title":"Expert Rev. Vaccines"},{"key":"1014_CR5","doi-asserted-by":"publisher","unstructured":"Fulton, B. O., Sun, W., Heaton, N. S. & Palese, P. The Influenza B Virus Hemagglutinin Head Domain Is Less Tolerant to Transposon Mutagenesis than That of the Influenza A Virus. J. Virol. 92, https:\/\/doi.org\/10.1128\/JVI.00754-18 (2018).","DOI":"10.1128\/JVI.00754-18"},{"key":"1014_CR6","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1071\/MA21033","volume":"42","author":"M Koutsakos","year":"2021","unstructured":"Koutsakos, M. & Kent, S. J. Influenza B viruses: underestimated and overlooked. Microbiol. Aust. 42, 110\u2013115 (2021).","journal-title":"Microbiol. Aust."},{"key":"1014_CR7","doi-asserted-by":"publisher","first-page":"119","DOI":"10.2217\/fmb.15.120","volume":"11","author":"M Koutsakos","year":"2016","unstructured":"Koutsakos, M., Nguyen, T. H., Barclay, W. S. & Kedzierska, K. Knowns and unknowns of influenza B viruses. Future Microbiol. 11, 119\u2013135 (2016).","journal-title":"Future Microbiol."},{"key":"1014_CR8","doi-asserted-by":"publisher","first-page":"5086","DOI":"10.1016\/j.vaccine.2007.03.046","volume":"25","author":"NA Molinari","year":"2007","unstructured":"Molinari, N. A. et al. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 25, 5086\u20135096 (2007).","journal-title":"Vaccine"},{"key":"1014_CR9","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1017\/S095026880800126X","volume":"137","author":"F Dijkstra","year":"2009","unstructured":"Dijkstra, F., Donker, G. A., Wilbrink, B., Van Gageldonk-Lafeber, A. B. & Van Der Sande, M. A. Long time trends in influenza-like illness and associated determinants in The Netherlands. Epidemiol. Infect. 137, 473\u2013479 (2009).","journal-title":"Epidemiol. Infect."},{"key":"1014_CR10","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1093\/cid\/ciu664","volume":"59","author":"H Terho","year":"2014","unstructured":"Terho, H., Niina, I. & Ziegler, T. Impact of Influenza B Lineage-Level Mismatch Between Trivalent Seasonal Influenza Vaccines and Circulating Viruses, 1999\u20132012. Clin. Infect. Dis. 59, 1519\u20131524 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"1014_CR11","first-page":"313","volume":"7","author":"K Herman","year":"2012","unstructured":"Herman, K. et al. Surveillance of Influenza in Indonesia, 2003\u20132007. Influenza Other Resp. 7, 313\u2013320 (2012).","journal-title":"Influenza Other Resp."},{"key":"1014_CR12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/0042-6822(90)90186-U","volume":"175","author":"AR Paul","year":"1990","unstructured":"Paul, A. R. et al. Cocirculation of Two Distinct Evolutionary Lineages of Influenza Type B Virus since 1983. Virology 175, 59\u201368 (1990).","journal-title":"Virology"},{"key":"1014_CR13","unstructured":"WHO. Global Influenza Programme, https:\/\/www.who.int\/tools\/flunet (2024)."},{"key":"1014_CR14","first-page":"e01673","volume":"93","author":"S Weina","year":"2018","unstructured":"Weina, S. et al. Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. J. Virol. 93, e01673\u201301618 (2018).","journal-title":"J. Virol."},{"key":"1014_CR15","doi-asserted-by":"publisher","first-page":"13107","DOI":"10.1128\/JVI.02148-13","volume":"87","author":"OP Zhirnov","year":"2013","unstructured":"Zhirnov, O. P. & Klenk, H. D. Influenza A virus proteins NS1 and hemagglutinin along with M2 are involved in stimulation of autophagy in infected cells. J. Virol. 87, 13107\u201313114 (2013).","journal-title":"J. Virol."},{"key":"1014_CR16","doi-asserted-by":"publisher","first-page":"3011","DOI":"10.1128\/JVI.02477-07","volume":"82","author":"W Qinghua","year":"2008","unstructured":"Qinghua, W., Feng, C., Mingyang, L., Xia, T. & Ma, J. Crystal Structure of Unliganded Influenza B Virus Hemagglutinin. J. Virol. 82, 3011\u20133020 (2008).","journal-title":"J. Virol."},{"key":"1014_CR17","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. Development of Influenza B Universal Vaccine Candidates Using the \u201cMosaic\u201d Hemagglutinin Approach. J. Virol. 93, https:\/\/doi.org\/10.1128\/JVI.00333-19 (2019).","DOI":"10.1128\/JVI.00333-19"},{"key":"1014_CR18","doi-asserted-by":"publisher","first-page":"746447","DOI":"10.3389\/fimmu.2021.746447","volume":"12","author":"Y Liu","year":"2021","unstructured":"Liu, Y. et al. Mosaic Hemagglutinin-Based Whole Inactivated Virus Vaccines Induce Broad Protection Against Influenza B Virus Challenge in Mice. Front. Immunol. 12, 746447 (2021).","journal-title":"Front. Immunol."},{"key":"1014_CR19","doi-asserted-by":"publisher","first-page":"1097349","DOI":"10.3389\/fbioe.2023.1097349","volume":"11","author":"E Puente-Massaguer","year":"2023","unstructured":"Puente-Massaguer, E. et al. Bioprocess development for universal influenza vaccines based on inactivated split chimeric and mosaic hemagglutinin viruses. Front Bioeng. Biotechnol. 11, 1097349 (2023).","journal-title":"Front Bioeng. Biotechnol."},{"key":"1014_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.vaccine.2020.12.018","volume":"39","author":"E Sparrow","year":"2021","unstructured":"Sparrow, E. et al. Global production capacity of seasonal and pandemic influenza vaccines in 2019. Vaccine 39, 512\u2013520 (2021).","journal-title":"Vaccine"},{"key":"1014_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24566-y","volume":"12","author":"MC Vieira","year":"2021","unstructured":"Vieira, M. C. et al. Lineage-specific protection and immune imprinting shape the age distributions of influenza B cases. Nat. Commun. 12, 4313 (2021).","journal-title":"Nat. Commun."},{"key":"1014_CR22","doi-asserted-by":"publisher","unstructured":"Edler, P. et al. Differential cross-reactivity to the influenza B virus haemagglutinin underpins lineage-specific susceptibility between birth cohorts, https:\/\/doi.org\/10.1101\/2023.08.25.554879 (2023).","DOI":"10.1101\/2023.08.25.554879"},{"key":"1014_CR23","doi-asserted-by":"publisher","first-page":"eadi4753","DOI":"10.1126\/sciadv.adi4753","volume":"9","author":"E Puente-Massaguer","year":"2023","unstructured":"Puente-Massaguer, E. et al. Chimeric hemagglutinin split vaccines elicit broadly cross-reactive antibodies and protection against group 2 influenza viruses in mice. Sci. Adv. 9, eadi4753 (2023).","journal-title":"Sci. Adv."},{"key":"1014_CR24","doi-asserted-by":"publisher","first-page":"3363","DOI":"10.1016\/j.vaccine.2013.05.007","volume":"31","author":"C Samuele","year":"2013","unstructured":"Samuele, C. et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion formulation,none of the individual components induce a comparable adjuvant effect. Vaccine 31, 3363\u20133369 (2013).","journal-title":"Vaccine"},{"key":"1014_CR25","doi-asserted-by":"publisher","first-page":"4992","DOI":"10.1172\/JCI122895","volume":"128","author":"STH Liu","year":"2018","unstructured":"Liu, S. T. H. et al. Antigenic sites in influenza H1 hemagglutinin display species-specific immunodominance. J. Clin. Invest 128, 4992\u20134996 (2018).","journal-title":"J. Clin. Invest"},{"key":"1014_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0126-4","volume":"4","author":"F Broecker","year":"2019","unstructured":"Broecker, F. et al. A mosaic hemagglutinin-based influenza virus vaccine candidate protects mice from challenge with divergent H3N2 strains. NPJ Vaccines 4, 31 (2019).","journal-title":"NPJ Vaccines"},{"key":"1014_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1016\/j.vaccine.2016.11.082","volume":"35","author":"RD de Vries","year":"2017","unstructured":"de Vries, R. D. et al. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. Vaccine 35, 238\u2013247 (2017).","journal-title":"Vaccine"},{"key":"1014_CR28","doi-asserted-by":"publisher","unstructured":"Ermler, M. E. et al. Chimeric Hemagglutinin Constructs Induce Broad Protection against Influenza B Virus Challenge in the Mouse Model. J. Virol. 91, https:\/\/doi.org\/10.1128\/JVI.00286-17 (2017).","DOI":"10.1128\/JVI.00286-17"},{"key":"1014_CR29","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.1073\/pnas.1609316113","volume":"113","author":"W He","year":"2016","unstructured":"He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl Acad. Sci. USA 113, 11931\u201311936 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1014_CR30","doi-asserted-by":"publisher","unstructured":"Jacobsen, H. et al. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge Model. mBio 8, https:\/\/doi.org\/10.1128\/mBio.01463-17 (2017).","DOI":"10.1128\/mBio.01463-17"},{"key":"1014_CR31","doi-asserted-by":"publisher","first-page":"469","DOI":"10.4049\/jimmunol.1400432","volume":"193","author":"S Jegaskanda","year":"2014","unstructured":"Jegaskanda, S., Reading, P. C. & Kent, S. J. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine. J. Immunol. 193, 469\u2013475 (2014).","journal-title":"J. Immunol."},{"key":"1014_CR32","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.3389\/fimmu.2019.01457","volume":"10","author":"TA Von Holle","year":"2019","unstructured":"Von Holle, T. A. & Moody, M. A. Influenza and Antibody-Dependent Cellular Cytotoxicity. Front Immunol. 10, 1457 (2019).","journal-title":"Front Immunol."},{"key":"1014_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.0300-9475.2004.01382.x","volume":"59","author":"RJ Cox","year":"2004","unstructured":"Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand. J. Immunol. 59, 1\u201315 (2004).","journal-title":"Scand. J. Immunol."},{"key":"1014_CR34","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/j.1365-3083.2005.01666.x","volume":"62","author":"AO Hovden","year":"2005","unstructured":"Hovden, A. O., Cox, R. J., Madhun, A. & Haaheim, L. R. Two doses of parenterally administered split influenza virus vaccine elicited high serum IgG concentrations which effectively limited viral shedding upon challenge in mice. Scand. J. Immunol. 62, 342\u2013352 (2005).","journal-title":"Scand. J. Immunol."},{"key":"1014_CR35","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.4049\/jimmunol.1402604","volume":"195","author":"G Lofano","year":"2015","unstructured":"Lofano, G. et al. Oil-in-Water Emulsion MF59 Increases Germinal Center B Cell Differentiation and Persistence in Response to Vaccination. J. Immunol. 195, 1617\u20131627 (2015).","journal-title":"J. Immunol."},{"key":"1014_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-021-00418-0","volume":"6","author":"DT O\u2019Hagan","year":"2021","unstructured":"O\u2019Hagan, D. T., van der Most, R., Lodaya, R. N., Coccia, M. & Lofano, G. \u201cWorld in motion\u201d - emulsion adjuvants rising to meet the pandemic challenges. NPJ Vaccines 6, 158 (2021).","journal-title":"NPJ Vaccines"},{"key":"1014_CR37","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/nm.3350","volume":"19","author":"S Sridhar","year":"2013","unstructured":"Sridhar, S. et al. Cellular immune correlates of protection against symptomatic pandemic influenza. Nat. Med 19, 1305\u20131312 (2013).","journal-title":"Nat. Med"},{"key":"1014_CR38","doi-asserted-by":"publisher","first-page":"2061","DOI":"10.1099\/vir.0.000156","volume":"96","author":"CE van de Sandt","year":"2015","unstructured":"van de Sandt, C. E. et al. Influenza B virus-specific CD8\u2009+\u2009T-lymphocytes strongly cross-react with viruses of the opposing influenza B lineage. J. Gen. Virol. 96, 2061\u20132073 (2015).","journal-title":"J. Gen. Virol."},{"key":"1014_CR39","doi-asserted-by":"publisher","first-page":"11760","DOI":"10.1128\/JVI.01631-14","volume":"88","author":"L Chen","year":"2014","unstructured":"Chen, L. et al. Immunodominant CD4\u2009+\u2009T-cell responses to influenza A virus in healthy individuals focus on matrix 1 and nucleoprotein. J. Virol. 88, 11760\u201311773 (2014).","journal-title":"J. Virol."},{"key":"1014_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0140-6736(22)00055-1","volume":"399","author":"L Bravo","year":"2022","unstructured":"Bravo, L. et al. Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial. Lancet 399, 461\u2013472 (2022).","journal-title":"Lancet"},{"key":"1014_CR41","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/S0140-6736(21)00241-5","volume":"397","author":"P Richmond","year":"2021","unstructured":"Richmond, P. et al. Safety and immunogenicity of S-Trimer (SCB-2019), a protein subunit vaccine candidate for COVID-19 in healthy adults: a phase 1, randomised, double-blind, placebo-controlled trial. Lancet 397, 682\u2013694 (2021).","journal-title":"Lancet"},{"key":"1014_CR42","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1473-3099(22)00144-X","volume":"22","author":"I Smolenov","year":"2022","unstructured":"Smolenov, I. et al. Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial. Lancet Infect. Dis. 22, 990\u20131001 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"1014_CR43","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. Antibody Responses toward the Major Antigenic Sites of Influenza B Virus Hemagglutinin in Mice, Ferrets, and Humans. J. Virol. 93, https:\/\/doi.org\/10.1128\/JVI.01673-18 (2019).","DOI":"10.1128\/JVI.01673-18"},{"key":"1014_CR44","unstructured":"FDA. Vaccines Licensed for Use in the United States, https:\/\/www.fda.gov\/vaccines-blood-biologics\/vaccines\/vaccines-licensed-use-united-states (2023)."},{"key":"1014_CR45","doi-asserted-by":"publisher","unstructured":"Roubidoux, E. K. & Schultz-Cherry, S. Animal Models Utilized for the Development of Influenza Virus Vaccines. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9070787 (2021).","DOI":"10.3390\/vaccines9070787"},{"key":"1014_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/nrd4529","volume":"14","author":"F Krammer","year":"2015","unstructured":"Krammer, F. & Palese, P. Advances in the development of influenza virus vaccines. Nat. Rev. Drug Discov. 14, 167\u2013182 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1014_CR47","doi-asserted-by":"publisher","first-page":"e0150700","DOI":"10.1371\/journal.pone.0150700","volume":"11","author":"TC Kon","year":"2016","unstructured":"Kon, T. C. et al. Influenza Vaccine Manufacturing: Effect of Inactivation, Splitting and Site of Manufacturing. Comparison of Influenza Vaccine Production Processes. PLoS One 11, e0150700 (2016).","journal-title":"PLoS One"},{"key":"1014_CR48","doi-asserted-by":"publisher","first-page":"10988","DOI":"10.1128\/JVI.01064-12","volume":"86","author":"V Jeisy-Scott","year":"2012","unstructured":"Jeisy-Scott, V. et al. TLR7 recognition is dispensable for influenza virus A infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice. J. Virol. 86, 10988\u201310998 (2012).","journal-title":"J. Virol."},{"key":"1014_CR49","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1128\/CVI.00816-13","volume":"21","author":"AJ Zhang","year":"2014","unstructured":"Zhang, A. J. et al. Toll-like receptor 7 agonist imiquimod in combination with influenza vaccine expedites and augments humoral immune responses against influenza A(H1N1)pdm09 virus infection in BALB\/c mice. Clin. Vaccin. Immunol. 21, 570\u2013579 (2014).","journal-title":"Clin. Vaccin. Immunol."},{"key":"1014_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-024-01732-8","author":"P Edler","year":"2024","unstructured":"Edler, P. et al. Immune imprinting in early life shapes cross-reactivity to influenza B virus haemagglutinin. Nat. Microbiol. https:\/\/doi.org\/10.1038\/s41564-024-01732-8 (2024).","journal-title":"Nat. Microbiol."},{"key":"1014_CR51","doi-asserted-by":"publisher","first-page":"974016","DOI":"10.3389\/fimmu.2022.974016","volume":"13","author":"S Jangra","year":"2022","unstructured":"Jangra, S. et al. RIG-I and TLR-7\/8 agonists as combination adjuvant shapes unique antibody and cellular vaccine responses to seasonal influenza vaccine. Front. Immunol. 13, 974016 (2022).","journal-title":"Front. Immunol."},{"key":"1014_CR52","doi-asserted-by":"publisher","unstructured":"Li, Z., Zhao, Y., Li, Y. & Chen, X. Adjuvantation of Influenza Vaccines to Induce Cross-Protective Immunity. Vaccines (Basel) 9, https:\/\/doi.org\/10.3390\/vaccines9020075 (2021).","DOI":"10.3390\/vaccines9020075"},{"key":"1014_CR53","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1086\/317537","volume":"32","author":"B Spellberg","year":"2001","unstructured":"Spellberg, B. & Edwards, J. E. Jr Type 1\/Type 2 immunity in infectious diseases. Clin. Infect. Dis. 32, 76\u2013102 (2001).","journal-title":"Clin. Infect. Dis."},{"key":"1014_CR54","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1017\/S0950268800050779","volume":"110","author":"AS Monto","year":"1993","unstructured":"Monto, A. S. & Sullivan, K. M. Acute respiratory illness in the community. Frequency of illness and the agents involved. Epidemiol. Infect. 110, 145\u2013160 (1993).","journal-title":"Epidemiol. Infect."},{"key":"1014_CR55","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41591-020-1118-7","volume":"27","author":"R Nachbagauer","year":"2021","unstructured":"Nachbagauer, R. et al. A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trial. Nat. Med 27, 106\u2013114 (2021).","journal-title":"Nat. Med"},{"key":"1014_CR56","doi-asserted-by":"publisher","unstructured":"Nachbagauer, R. et al. A chimeric haemagglutinin-based influenza split virion vaccine adjuvanted with AS03 induces protective stalk-reactive antibodies in mice. NPJ Vaccines 1. https:\/\/doi.org\/10.1038\/npjvaccines.2016.15 (2016).","DOI":"10.1038\/npjvaccines.2016.15"},{"key":"1014_CR57","doi-asserted-by":"publisher","unstructured":"Sun, W. et al. A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines 8, https:\/\/doi.org\/10.3390\/vaccines8040771 (2020).","DOI":"10.3390\/vaccines8040771"},{"key":"1014_CR58","first-page":"e01696","volume":"93","author":"A Guha Asthagiri","year":"2019","unstructured":"Guha Asthagiri, A. et al. Broadly Cross-Reactive, Nonneutralizing Antibodies against Influenza B Virus Hemagglutinin Demonstrate Effector Function-Dependent Protection against Lethal Viral Challenge in Mice. J. Virol. 93, e01696\u201301618 (2019).","journal-title":"J. Virol."},{"key":"1014_CR59","doi-asserted-by":"publisher","unstructured":"Kirkpatrick, E. et al. Characterization of Novel Cross-Reactive Influenza B Virus Hemagglutinin Head Specific Antibodies That Lack Hemagglutination Inhibition Activity. J. Virol. 94, https:\/\/doi.org\/10.1128\/JVI.01185-20 (2020).","DOI":"10.1128\/JVI.01185-20"},{"key":"1014_CR60","doi-asserted-by":"publisher","unstructured":"Margine, I., Palese, P. & Krammer, F. Expression of functional recombinant hemagglutinin and neuraminidase proteins from the novel H7N9 influenza virus using the baculovirus expression system. J. Vis. Exp., e51112 https:\/\/doi.org\/10.3791\/51112 (2013).","DOI":"10.3791\/51112"},{"key":"1014_CR61","doi-asserted-by":"publisher","unstructured":"McKay, P. F. et al. Identification of potential biomarkers of vaccine inflammation in mice. Elife 8, https:\/\/doi.org\/10.7554\/eLife.46149 (2019).","DOI":"10.7554\/eLife.46149"},{"key":"1014_CR62","doi-asserted-by":"publisher","first-page":"729189","DOI":"10.3389\/fimmu.2021.729189","volume":"12","author":"S Jangra","year":"2021","unstructured":"Jangra, S. et al. A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. Front Immunol. 12, 729189 (2021).","journal-title":"Front Immunol."},{"key":"1014_CR63","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/molbev\/msab120","volume":"38","author":"K Tamura","year":"2021","unstructured":"Tamura, K., Stecher, G. & Kumar, S. MEGA11: Molecular Evolutionary Genetics Analysis Version 11. Mol. Biol. Evol. 38, 3022\u20133027 (2021).","journal-title":"Mol. Biol. Evol."},{"key":"1014_CR64","first-page":"512","volume":"10","author":"K Tamura","year":"1993","unstructured":"Tamura, K. & Nei, M. Estimation of the number of nucleotide substitutions in the control region of mitochondrial DNA in humans and chimpanzees. Mol. Biol. Evol. 10, 512\u2013526 (1993).","journal-title":"Mol. Biol. Evol."},{"key":"1014_CR65","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-10-356","volume":"10","author":"MV Han","year":"2009","unstructured":"Han, M. V. & Zmasek, C. M. phyloXML: XML for evolutionary biology and comparative genomics. BMC Bioinforma. 10, 356, (2009).","journal-title":"BMC Bioinforma."},{"key":"1014_CR66","doi-asserted-by":"publisher","first-page":"6 14 11","DOI":"10.1002\/0471250953.bi0614s51","volume":"51","author":"A Stamatakis","year":"2015","unstructured":"Stamatakis, A. Using RAxML to Infer Phylogenies. Curr. Protoc. Bioinforma. 51, 6 14 11\u201316 14 14, (2015).","journal-title":"Curr. Protoc. Bioinforma."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01014-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01014-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T09:05:17Z","timestamp":1732093517000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-024-01014-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,17]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1014"],"URL":"https:\/\/doi.org\/10.1038\/s41541-024-01014-8","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,17]]},"assertion":[{"value":"29 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The Icahn School of Medicine at Mount Sinai and Dynavax have filed a patent application in which P.P., W.S., I.G.D. and F.K. are listed as co-inventors. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays, NDV-based SARS-CoV-2 vaccines, influenza virus vaccines and influenza virus therapeutics which list F.K. as co-inventor. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2 and another company, Castlevax, to develop SARS-CoV-2 vaccines. F.K., P.P. and W.S. are co-founder of Castlevax. F.K. has consulted for Merck, Curevac, Seqirus and Pfizer and is currently consulting for 3rd Rock Ventures, GSK, Gritstone and Avimex. The Krammer laboratory is also collaborating with Dynavax on influenza A virus vaccine development. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"222"}}